Omalizumab in patients with severe asthma and persistent sputum eosinophilia.

Authors:
Manali Mukherjee
Manali Mukherjee
Firestone Institute for Respiratory Health
Melanie Kjarsgaard
Melanie Kjarsgaard
McMaster University
Canada
Katherine Radford
Katherine Radford
Firestone Institute for Respiratory Health
Canada
Chynna Huang
Chynna Huang
McMaster University
Richard Leigh
Richard Leigh
University of Calgary
Canada
Delbert R Dorscheid
Delbert R Dorscheid
University of British Columbia
Canada
Catherine Lemiere
Catherine Lemiere
Sacré-Coeur Hospital
Canada

Allergy Asthma Clin Immunol 2019 3;15:21. Epub 2019 Apr 3.

1Department of Medicine, Division of Respirology, McMaster University, Hamilton, ON Canada.

Omalizumab, a recombinant humanized monoclonal antibody targeting the IgE molecule, is the first biologic approved for moderate-to-severe allergic asthmatics, who remain uncontrolled despite high dose inhaled corticosteroid and bronchodilators. Steroid-sparing effect of omalizumab has not been demonstrated in asthmatics with persistent airway eosinophilia in a randomised controlled trial till date. From this double-blind, placebo-controlled, multi-centred, randomized parallel group design, we report that omalizumab is possibly inadequate to control sputum eosinophilia, and therefore may not have a steroid-sparing effect, especially in those maintained on oral corticosteroids daily. This needs to be confirmed or refuted in a larger trial, which may be a challenge with respect to recruitment, since there are currently three additional biologics available to prescribe. Clinicaltrials.gov, NCT02049294, Registered 30th January 2014, https://clinicaltrials.gov/ct2/show/NCT02049294.

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13223-019-0337-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448265PMC
April 2019
5 Reads

Article Mentions


Provided by Crossref Event Data
datacite
Datacite: Datacite
April 4, 2019, 12:41 am EST

Publication Analysis

Top Keywords

sputum eosinophilia
8
omalizumab inadequate
4
steroid-sparing omalizumab
4
bronchodilators steroid-sparing
4
omalizumab demonstrated
4
demonstrated asthmatics
4
persistent airway
4
recruitment currently
4
asthmatics persistent
4
corticosteroid bronchodilators
4
currently three
4
despite high
4
additional biologics
4
uncontrolled despite
4
inadequate control
4
high dose
4
inhaled corticosteroid
4
dose inhaled
4
three additional
4
airway eosinophilia
4

References

(Supplied by CrossRef)
Article in Ann Intern Med
NA Hanania et al.
Ann Intern Med 2011
Article in Cochrane Database Syst Rev
R Normansell et al.
Cochrane Database Syst Rev 2014
Article in Am J Respir Crit Care Med
R Djukanović et al.
Am J Respir Crit Care Med 2004
Article in J Allergy Clin Immunol
SG Smith et al.
J Allergy Clin Immunol 2015
Article in N Engl J Med
GM Gauvreau et al.
N Engl J Med 2014
Article in Am J Respir Crit Care Med
K Parameswaran et al.
Am J Respir Crit Care Med 2004
Article in Eur Respir J
A Dasgupta et al.
Eur Respir J 2013

Similar Publications